Scarica l'app Stockscreener
3.07
12.45%
0.34
Dopo l'orario di chiusura:
3.26
0.19
+6.19%
Prime Medicine Inc Borsa (PRME) Ultime notizie
Prime Medicine’s SWOT analysis: gene editing firm faces cash crunch amid promising tech - Investing.com
Prime Medicine’s Technological Edge and Strategic Positioning Highlighted as Key Investment Opportunity - TipRanks
Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires $33,600.00 in Stock - MarketBeat
Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty - MSN
Two Sigma Advisers LP Sells 76,700 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine, Inc. (NYSE:PRME) Receives $10.08 Average PT from Brokerages - Defense World
Prime Medicine stock plummets amid restructuring and leadership changes - MSN
Bank of America Corp DE Trims Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Layoff Tracker: Capsida Downsizes as Part of Shift to Clinical-Stage Company - BioSpace
Prime Medicine Elects Directors at Annual Meeting - TipRanks
20,096 Shares in Prime Medicine, Inc. (NYSE:PRME) Bought by BNP Paribas Financial Markets - Defense World
Jane Street Group LLC Boosts Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Deutsche Bank AG Cuts Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Altria, Prime Medicine, US Steel, DLocal, Prothena: Trending by Analysts - TipRanks
Prime Medicine Announces Key Presentations at Two Major Healthcare Investor Conferences in June - Stock Titan
Prime Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Prime Medicine’s (PRME) Neutral Rating Reaffirmed at Citigroup - Defense World
Citigroup Downgrades Prime Medicine (PRME) Amid Significant Pric - GuruFocus
Prime Medicine’s SWOT analysis: gene editing firm shifts focus, stock faces challenges By Investing.com - Investing.com South Africa
Citigroup Downgrades Prime Medicine to Neutral From Buy, Adjusts Price Target to $1.50 From $10 - marketscreener.com
Prime Medicine’s SWOT analysis: gene editing firm shifts focus, stock faces challenges - Investing.com Canada
Prime Medicine (PRME) Downgraded by Citi with Reduced Price Targ - GuruFocus
Prime Medicine (PRME) Downgraded by Citi with Reduced Price Target | PRME Stock News - GuruFocus
Prime Medicine downgraded to Neutral from Buy at Citi - TipRanks
Hold Rating for Prime Medicine, Inc. Amid Financial Uncertainties and Strategic Adjustments - TipRanks
Prime Medicine (NYSE:PRME) Earns "Neutral" Rating from JPMorgan Chase & Co. - MarketBeat
Prime Medicine FY2025 EPS Estimate Raised by Chardan Capital - Defense World
Hold Rating on Prime Medicine, Inc. Amid Strategic Shifts and Financial Reevaluation - TipRanks
Critical Analysis: Prime Medicine (NYSE:PRME) and Vigil Neuroscience (NASDAQ:VIGL) - Defense World
Prime Medicine Executives Make Bold Stock Purchases! - TipRanks
Insider Buying: Ann Lee Acquires 100,000 Shares of Prime Medicine Inc (PRME) - GuruFocus
Prime Medicine Executives Make Significant Stock Purchases - TradingView
Prime Medicine CEO Acquires 125,000 Shares - TradingView
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - TradingView
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish - MSN
Prime Medicine Cuts Workforce By 25% In Strategic Shift - Finimize
CEO among 25% of staff out the door at cash-strapped Prime - The Pharma Letter
Prime Medicine (PRME) Sees Price Target Adjustment by JMP Securities | PRME Stock News - GuruFocus
This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Prime Medicine (PRME) Receives Downgrade from JP Morgan | PRME Stock News - GuruFocus
PRME: Prime Medicine Downgraded to Neutral by HC Wainwright & Co - GuruFocus
Prime Medicine downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Prime Medicine (PRME) Faces Downgrade Amid Strategic Shift | PRM - GuruFocus
Prime Medicine (PRME) Adjusts Strategy Amid Leadership Changes | - GuruFocus
Prime Medicine price target lowered to $6 from $10 at Citizens JMP - TipRanks
Prime Medicine, Inc.: Hold Rating Amid Strategic Restructuring and Long-term Uncertainty - TipRanks
Prime Medicine refocuses on liver disease, leadership changes By Investing.com - Investing.com South Africa
PRME Downgraded by JPMorgan Amid Strategic Shift | PRME Stock News - GuruFocus
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):